US 12043629
RIP1K inhibitors
granted A61KA61K9/0053A61P
Quick answer
US patent 12043629 (RIP1K inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61K, A61K9/0053, A61P, A61P17/00, A61P25/00